Immunorhelins Peptide Selective GnRH II Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV are compromised by patient compliance issues, drug toxicity, and drug resistance, and existing treatments for HIV and cancer do not effectively enhance the immune competence of CD4+ T cells, which are key mediators of the immune response.
Innovation Solution
Development of novel GnRH II-like peptides, termed immunorhelins, which stimulate MHC class I expression on T cells, thereby enhancing immune responses while minimizing hormonal side effects by preferentially binding to GnRH II receptors over GnRH I receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GnRH I receptor agonists are used to stimulate immune responses, then immune competence is enhanced, but unwanted endocrine effects and hormonal side effects occur
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid substitutions at particular positions (e.g., position 2, 5, 6, 9) to achieve selective binding to GnRH II receptors. This localized modification approach ensures that only specific receptor subtypes are activated, enhancing immune responses while avoiding endocrine effects mediated by GnRH I receptors.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid residues at specific positions in the GnRH II-like peptide sequence. These parameter modifications (substituting different amino acids at key positions) alter the peptide's binding affinity and selectivity, enabling preferential interaction with GnRH II receptors over GnRH I receptors, thus achieving immune stimulation without hormonal side effects.
2Reliability
If GnRH I analogs are administered at high levels to stimulate immune system, then immune response is enhanced, but inhibitory effect on GnRH I receptors causes pharmacological castration
Solution Approach 1:
The patent uses GnRH II-like peptides as intermediaries that selectively activate GnRH II receptors expressed on immune cells. This intermediary approach allows immune stimulation to occur through a different receptor pathway (GnRH II) that does not trigger the endocrine cascade associated with GnRH I receptor activation, thereby avoiding pharmacological castration while maintaining immune enhancement.
Solution Approach 2:
Instead of using GnRH I analogs that activate the classical endocrine pathway, the patent inverts the approach by utilizing GnRH II-like peptides that activate a non-endocrine pathway. This inversion allows the same immune-stimulating effect to be achieved through the alternative GnRH II receptor pathway, avoiding the harmful effects of GnRH I receptor overactivation.
3Reliability
If existing antiretroviral therapy is used for HIV treatment, then viral replication is controlled, but patient compliance and drug resistance issues arise
Solution Approach 1:
The patent employs immunorhelins that stimulate the patient's own immune system to control HIV replication, rather than relying solely on external antiretroviral drugs. By enhancing the body's natural immune competence through GnRH II-like peptide stimulation of immune cells, the treatment leverages the patient's self-defensive mechanisms, potentially reducing dependency on complex drug regimens and improving compliance.
Solution Approach 2:
The patent applies multi-functionality by using GnRH II-like peptides that can stimulate various immune cell types (T cells, B cells, macrophages) simultaneously. This broad immune activation provides a comprehensive antiviral effect that complements specific antiretroviral therapies, creating a multi-pronged approach to HIV control that may reduce drug resistance and improve overall treatment efficacy.
Data Source
AI summary
The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.